3Z and biotx.ai join forces in a strategic partnership

Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge the gap between animal studies and human clinical trials, enabling a more efficient and accurate translation...

The post 3Z and biotx.ai join forces in a strategic partnership first appeared on AI-TechPark.

adhd advanced advanced ai ai bridge causal ai clinical trials collaboration development discovery drug development drug discovery enabling gap germany human join modelling partnership studies translation